Vir Biotechnology, Inc. (VIR)
- Sector
- Biotechnology
- Last price
- $10.61
- As of
Kresmion compiles this page from VIR's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Vir Biotechnology, Inc. (VIR): 6 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-14.
See the full VIR dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for VIR on one page. Preview it with sample data, then open it live with a free account.
Preview the VIR dossierActive signals for VIR
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +283% to VIR (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +7032% to VIR (2026Q2)
- highINSTITUTIONAL_SURGE
Point72 Asset Management, L.P. added +190% to VIR (2026Q2)
- highINSTITUTIONAL_EXIT
MILLENNIUM MANAGEMENT LLC cut 90% of VIR (2026Q2)
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 39.8%, EPS $0.47 vs $0.3363 estimate
FREE, NO ACCOUNT
Every signal on VIR, as it fires
You are seeing 5 of 12 signals recorded on VIR since 2026-05-24.
The five above landed across 2 days. The other 7 were recorded on 2 other days. 7 of the 12 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in VIR (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| Point72 Asset Management, L.P.CUSIP 92764N102 · 2026Q2 | $57.7M | 0.06% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 92764N102 · 2026Q2 | $11.3M | 0.01% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 92764N102 · 2026Q2 | $10.4M | 0.01% | , |
| CITADEL ADVISORS LLCCUSIP 92764N102 · 2026Q2 | $10.1M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 92764N102 · 2026Q2 | $4.2M | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 92764N102 · 2026Q2 | $489K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, VIR
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
VIR against its peers
VIR's operating margin of -699.2% ranks in the 26th percentile of 16 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2025-12-31.
| Metric | VIR | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 68.6M USD | 95.0M USD | 38 | 16 |
| Operating margin | -699.2% | -127.5% | 26 | 16 |
| Net margin | -638.9% | -106.4% | 25 | 17 |
| Return on equity | -57.2% | -34.6% | 33 | 19 |
| 1 year | 81.1% | 25.4% | 83 | 19 |
Peers (22): PVLA, LKFT, VCEL, NVAX, MLYS, SRPT, AGIO, MESO, VRDN, ZYME, XNCR, BHVN, VERA, BCRX, URGN, PHVS, ZBIO, AUPH, SEPN, ABSI, IMNM, NRIX. Left out: ADRX (no annual filing), GENB (no annual filing), BRVE (no annual filing). Fiscal periods ending between 2025-06-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (VIR: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow VIR on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to VIR for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.